BRAF V600E in Cancer: Mechanism and Targeted Treatment

V600E Molecular Mechanism: Constitutive Monomer Activity

Wild-type BRAF is normally autoinhibited by a regulatory N-terminal region that contacts the kinase domain, and requires dimerisation with CRAF or another BRAF molecule for full activation. The V600E mutation inserts a negatively charged glutamate residue at position 600 within the DFG-containing activation loop, mimicking the phosphorylation-dependent activation that normally requires upstream RAS input. This structural mimicry stabilises the 'active' DFG-in kinase conformation constitutively, allowing BRAF V600E to signal as a monomer.

The monomer-active nature of BRAF V600E has pharmacological consequences: first-generation BRAF inhibitors can preferentially inhibit the mutant monomer. In cells with upstream RAS activity, RAF inhibitors can instead promote transactivation within RAF dimers and increase ERK signalling. This paradoxical activation helps explain some toxicities and why combination strategies are used in defined settings, but treatment requirements remain label- and disease-specific.

BRAF V600E Across Cancer Types and Therapeutic Responses

BRAF V600E is common in several molecular subgroups, including cutaneous melanoma, papillary thyroid carcinoma and hairy cell leukaemia, and occurs in a smaller subset of colorectal cancers. Frequency estimates vary with histology, classification and cohort. Treatment response also differs by lineage despite the same amino-acid change. In colorectal cancer, EGFR-mediated feedback helps explain the limited activity of BRAF inhibition alone and the study of BRAF- plus EGFR-directed combinations.

Resistance to BRAF/MEK inhibitors in melanoma arises through multiple mechanisms: reactivation of MAPK (secondary NRAS mutations, KRAS mutations, MEK1/MEK2 mutations, BRAF V600E amplification, BRAF alternative splicing), bypass signalling through PI3K/AKT/mTOR, and histological transformation. Triplet combinations (BRAF + MEK + anti-PD1) are being explored to delay resistance by simultaneously targeting oncogenic signalling and restoring immune surveillance.

BRAF Fusions and Non-V600 Alterations

Beyond V600E, class 2 BRAF mutations and fusions can signal as RAS-independent dimers, making their biology different from a class 1 V600 monomer. KIAA1549–BRAF is recurrent in paediatric low-grade glioma, but fusion partners, tumour setting and current product labelling all matter; a BRAF fusion should not be interpreted as V600E.

Class 3 BRAF variants have impaired or low kinase activity and can depend on upstream RAS activity and RAF dimers. This biology differs from V600E, but it does not create one tumour-agnostic MEK-inhibitor rule. Pan-RAF, RAF-dimer and downstream strategies remain dependent on variant, lineage and clinical evidence.

Key Takeaways

• ·BRAF V600E mimics activation loop phosphorylation, stabilising the active DFG-in kinase conformation and enabling constitutive monomeric signalling without RAS or dimerisation — a mechanism exploited by first-generation BRAF-selective inhibitors.
• ·RAF-inhibitor effects depend on dimer state and upstream RAS activity; combination requirements should be taken from a current disease-specific label or guideline.
• ·Response and resistance differ by tumour lineage, with EGFR feedback being especially important in BRAF V600E colorectal cancer.
• ·BRAF V600E occurs across melanoma, thyroid, colorectal, lung, brain and haematological cancers, but prevalence and treatment evidence differ substantially by lineage.
• ·BRAF fusions such as KIAA1549–BRAF activate signalling through a different dimer-dependent mechanism and should not be interpreted as V600E.